logo
Twitter
Discord
Email
logo
Omnicell, Inc.

Omnicell, Inc.

NASDAQ•OMCL
CEO: Mr. Randall A. Lipps
Sector: Healthcare
Industry: Medical - Healthcare Information Services
Listing Date: 2001-08-09
Omnicell, Inc., together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications. It also provides central pharmacy automation solutions; IV compounding robots; and inventory management software. In addition, the company provides single-dose automation solutions that fill and label a variety of patient-specific, single-dose medication blister packaging based on incoming prescriptions; fully automated and semi-automated filling equipment for institutional pharmacies to warrant automated packaging of medications; and medication blister card packaging and packaging supplies to enhance medication adherence in non-acute care settings. Further, it offers EnlivenHealth Patient Engagement, a web-based solutions. The company was formerly known as Omnicell Technologies, Inc. and changed its name to Omnicell, Inc. in 2001. Omnicell, Inc. was incorporated in 1992 and is headquartered in Fort Worth, Texas.
Contact Information
4220 North Freeway, Suite 301, Fort Worth, TX, 76137, United States
877-415-9990
www.omnicell.com
Market Cap
$2.31B
P/E (TTM)
116.9
47.3
Dividend Yield
--
52W High
$55.00
52W Low
$22.66
52W Range
85%
Rank31Top 21.6%
5.0
F-Score
Modified Piotroski Analysis
Based on 10-year fundamentals
Average • 5 / 9 points
Scoring Range (0-9)
8-9: Excellent Value
6-7: Strong Fundamentals
4-5: Average Quality
0-3: Weak Performance
Data Period: 2016-2025

Financial Dashboard

Q3 2025 Data

Revenue

$310.63M+9.99%
4-Quarter Trend

EPS

$0.12-36.84%
4-Quarter Trend

FCF

$18.51M+96.58%
4-Quarter Trend

2025 Q3 Earnings Highlights

Key Highlights

Revenue Growth Strong Total revenues reached $870.9 M USD, growing 8% for nine months. Gross profit increased 13% to $373.1 M USD.
Profitability Turnaround Swung to net income of $4.1 M USD for nine months, compared to $3.3 M USD loss previous period. Gross margin improved to 43%.
Strong Service Revenue Service revenues grew 8% to $385.0 M USD for nine months, driven by technical and SaaS/Expert Services demand.
Debt Reduction Activity Repaid $175.0 M USD principal balance of 2025 Convertible Senior Notes upon maturity in September 2025.

Risk Factors

International Sales Risks International operations face risks from reliance on distributors, managing foreign regulations, and currency fluctuations.
Supply Chain Cost Pressures Product costs impacted by potential price fluctuations, shortages of raw materials, and semiconductor chip supply requirements.
Capital Expenditure Demand Significant capital expenditure required for system modernization and automation adoption by healthcare facilities remains a risk.
Trade Restriction Uncertainty Ongoing US trade restrictions, tariffs, and potential retaliation create uncertainty impacting supply chain and cost forecasts.

Outlook

Autonomous Pharmacy Vision Strategy focuses on advancing Autonomous Pharmacy vision through robotics, smart devices, and workflow optimization investments.
Growth in Ambulatory Care Expect growth opportunities in Ambulatory Care, driven by retail pharmacy expansion and value-based care adoption trends.
Specialty Pharmacy Expansion Continued investment in Specialty Pharmacy and 340B Program solutions targeting complex condition medication management.
Liquidity Position Maintained Existing cash, operating cash flows, and $350.0 M USD available credit facility expected to fund needs for twelve months.

Peer Comparison

Revenue (TTM)

Astrana Health, Inc.ASTH
$2.90B
+68.2%
Teladoc Health, Inc.TDOC
$2.53B
-2.4%
Clover Health Investments, Corp.CLOV
$1.77B
+14.8%

Gross Margin (Latest Quarter)

GoodRx Holdings, Inc.GDRX
93.2%
-0.9pp
Teladoc Health, Inc.TDOC
70.1%
-1.8pp
Phreesia, Inc.PHR
68.4%
+0.7pp

Key Metrics

Symbol
Market Cap
P/E (TTM)
ROE (TTM)
Debt to Assets
TXG$2.83B-36.8-10.3%8.5%
OMCL$2.31B116.91.6%10.6%
ASTH$1.36B140.11.3%48.6%

Long-Term Trends

Last 4 Quarters
Revenue
Net Income
Operating Cash Flow
4Q Revenue CAGR
0.4%
Moderate Growth
4Q Net Income CAGR
-29.9%
Declining Profitability
Cash Flow Stability
100%
Strong Cash Flow

Research & Insights

Next earnings:Feb 5, 2026
|
EPS:$0.47
|
Revenue:-
Reports
All Years
  • Form 10-Q - Q3 2025

    Period End: Sep 30, 2025|Filed: Nov 5, 2025|
    Revenue: $310.63M+10.0%
    |
    EPS: $0.12-36.8%
    Miss
  • Form 10-Q - Q2 2025

    Period End: Jun 30, 2025|Filed: Aug 6, 2025|
    Revenue: $290.56M+5.0%
    |
    EPS: $0.12+47.6%
    Miss
  • Form 10-Q - Q1 2025

    Period End: Mar 31, 2025|Filed: May 7, 2025|
    Revenue: $269.67M+9.6%
    |
    EPS: $-0.15-55.9%
    Miss
  • Form 10-K - FY 2024

    Period End: Dec 31, 2024|Filed: Feb 27, 2025|
    Revenue: $1.11B-3.0%
    |
    EPS: $0.27+160.0%
    Miss
  • Form 10-Q - Q3 2024

    Period End: Sep 30, 2024|Filed: Nov 8, 2024|
    Revenue: $282.42M-5.4%
    |
    EPS: $0.19+58.3%
    Miss
  • Form 10-Q - Q2 2024

    Period End: Jun 30, 2024|Filed: Aug 6, 2024|
    Revenue: $276.79M-7.4%
    |
    EPS: $0.08+6.3%
    Miss
  • Form 10-Q - Q1 2024

    Period End: Mar 31, 2024|Filed: May 7, 2024|
    Revenue: $246.15M-15.3%
    |
    EPS: $-0.34+3.0%
    Miss
  • Form 10-K - FY 2023

    Period End: Dec 31, 2023|Filed: Feb 28, 2024|
    Revenue: $1.15B-11.5%
    |
    EPS: $-0.45-446.2%
    Miss